The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.
Werewolf Therapeutics, a US-based oncology therapy developer backed by pharmaceutical firm Taiho, filed for a $100m initial public offering (IPO) on the Nasdaq Global Market yesterday.
Founded by life sciences investment firm MPM Capital with an undisclosed amount of seed funding in 2017, Werewolf is developing cancer-focused biotherapeutics which involve using its protein engineering platform dubbed Predator to train the body’s immune response to target tumours.
The company will use the proceeds from the offering and existing cash on…
